ProQR Therapeutics (NASDAQ:PRQR) Receives "Buy" Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in a research report released on Thursday,Benzinga reports. The firm currently has a $4.00 price objective on the biopharmaceutical company's stock.

A number of other research firms have also recently weighed in on PRQR. HC Wainwright boosted their target price on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Raymond James upgraded ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. Finally, StockNews.com lowered ProQR Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, November 28th. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics has an average rating of "Moderate Buy" and an average price target of $7.60.

ProQR Therapeutics Trading Down 2.7 %

NASDAQ PRQR traded down $0.09 during trading on Thursday, hitting $3.29. 554,479 shares of the company's stock were exchanged, compared to its average volume of 520,463. The company has a market cap of $268.73 million, a PE ratio of -10.50 and a beta of 0.24. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62. The stock's 50 day moving average price is $3.36 and its two-hundred day moving average price is $2.38.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds have recently made changes to their positions in the stock. OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 15,550 shares during the period. BNP Paribas Financial Markets boosted its position in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 7,300 shares in the last quarter. Finally, Privium Fund Management B.V. boosted its position in shares of ProQR Therapeutics by 4.4% during the 2nd quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company's stock valued at $9,208,000 after purchasing an additional 236,279 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).